CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...